Multidisciplinary treatment of resectable rectal cancer

References

• National Cancer Institute. Cancer Topics: Colon and Rectal Cancer US National Institutes Of Health, MA, USA (2008).
   Google Scholar
• Wang SJ, Fuller CD, Emery R, Thomas CR, Jr. Conditional survival in rectal cancer: a SEER database analysis. Gastrointest. Cancer. Res.1(3), 84–89 (2007).
   PubMedGoogle Scholar
• Beets-Tan RG, Beets GL. Preoperative staging of rectal tumors: what is the most optimal staging method? Onkologie31(5), 222–223 (2008).
   PubMedGoogle Scholar
• Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study. BMJ333(7572), 779 (2006).
   PubMed Web of Science ®Google Scholar
• O’Neill BD, Salerno G, Thomas K, Tait DM, Brown G. MR vs CT imaging: low rectal cancer tumour delineation for three-dimensional conformal radiotherapy. Br. J. Radiol.82(978), 509–513 (2009).
   PubMed Web of Science ®Google Scholar
• Puli SR, Bechtold ML, Reddy JB et al. How good is endoscopic ultrasound in differentiating various T stages of rectal cancer? Meta-analysis and systematic review. Ann. Surg. Oncol.16(2), 254–265 (2008).
   PubMed Web of Science ®Google Scholar
• Tatli S, Mortele KJ, Breen EL, Bleday R, Silverman SG. Local staging of rectal cancer using combined pelvic phased-array and endorectal coil MRI. J. Magn. Reson. Imaging23(4), 534–540 (2006).
   PubMed Web of Science ®Google Scholar
• Rich T, Ota D, Rosenthal S et al. Management of resectable rectal cancer. American college of radiology. ACR appropriateness criteria. Radiology215(Suppl.), 1473–1480 (2000).
   PubMedGoogle Scholar
• Tepper J, Bader J, Janjan N et al. Locally unresectable rectal cancer. American College of Radiology. ACR Appropriateness Criteria. Radiology215(Suppl.), 1481–1490 (2000).
   PubMedGoogle Scholar
• Heald R, Ryall R. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet1, 1479–1482 (1986).
   PubMed Web of Science ®Google Scholar
• Heald R, Moran B, Ryall R et al. Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978–1997. Arch. Surg.133, 894–899 (1998).
   PubMed Web of Science ®Google Scholar
• Farid H, O’Connell T. Methods to decrease the morbidity of abdominoperineal resection. Am. Surg.61, 1061–1064 (1995).
   PubMed Web of Science ®Google Scholar
• Wibe A, Syse A, Andersen E et al. Oncological outcomes after total mesorectal excision for cure for cancer of the lower rectum: anterior vs. abdominoperineal resection. Dis. Colon Rectum47, 48–58 (2004).
   PubMed Web of Science ®Google Scholar
• Nagtegaal ID, van de Velde CJ, Marijnen CA, van Krieken JH, Quirke P. Low rectal cancer: a call for a change of approach in abdominoperineal resection. J. Clin. Oncol23(36), 9257–9264 (2005).
   PubMed Web of Science ®Google Scholar
• Solomon M, Pager C, Keshava A et al. What do patients want? Patient preferences and surrogate decision making in the treatment of colorectal cancer. Dis. Colon Rectum46, 1351–1357 (2003).
   PubMed Web of Science ®Google Scholar
• Endreseth B, Myrvold H, Romundstad P et al. Transanal excision vs. major surgery for T1 rectal cancer. Dis. Colon Rectum48, 1380–1388 (2005).
   PubMed Web of Science ®Google Scholar
• Minsky B, Rich T, Recht A et al. Selection criteria for local excision with or without adjuvant radiation therapy for rectal cancer. Cancer63, 1421–1429 (1989).
   PubMed Web of Science ®Google Scholar
• Endreseth BH, Wibe A, Svinsas M, Marvik R, Myrvold HE. Postoperative morbidity and recurrence after local excision of rectal adenomas and rectal cancer by transanal endoscopic microsurgery. Colorectal Dis.7(2), 133–137 (2005).
   PubMed Web of Science ®Google Scholar
• Lezoche E, Guerrieri M, Paganini AM, Feliciotti F. Long-term results of patients with pT2 rectal cancer treated with radiotherapy and transanal endoscopic microsurgical excision. World J Surg.26(9), 1170–1174 (2002).
   PubMed Web of Science ®Google Scholar
• Goes R, Beart R Jr, Simons A et al. Use of brachytherapy in management of locally recurrent rectal cancer. Dis. Colon Rectum.40, 1177–1179 (1997).
   PubMed Web of Science ®Google Scholar
• Grimard L, Stern H, Spaans JN. Brachytherapy and local excision for sphincter preservation in T1 and T2 rectal cancer. Int. J. Radiat. Oncol. Biol. Phys.74(3), 803–809 (2009).
   PubMed Web of Science ®Google Scholar
• Russell A, Harris J, Rosenberg P et al. Anal sphincter conservation for patients with adenocarcinoma of the distal rectum: long-term results of radiation therapy oncology group protocol 89–02. Int. J. Radiat. Oncol. Biol. Phys.46, 313–322 (2000).
   PubMed Web of Science ®Google Scholar
• Steele GD Jr, Herndon J, Bleday R et al. Sphincter-sparing treatment for distal rectal adenocarcinoma. Ann Surg Oncol.6, 433–441 (1999).
   PubMed Web of Science ®Google Scholar
• Prolongation of the disease-free interval in surgically treated rectal carcinoma. Gastrointestinal Tumor Study Group. N. Engl. J. Med.312(23), 1465–1472 (1985).
   PubMed Web of Science ®Google Scholar
• Tveit KM, Guldvog I, Hagen S et al. Randomized controlled trial of postoperative radiotherapy and short-term time-scheduled 5-fluorouracil against surgery alone in the treatment of Dukes B and C rectal cancer. Norwegian Adjuvant Rectal Cancer Project Group. Br. J. Surg.84(8), 1130–1135 (1997).
   PubMed Web of Science ®Google Scholar
• NIH Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA264, 1444–1150 (1990).
   PubMed Web of Science ®Google Scholar
• Wolmark N, Wieand H, Hyams D et al. Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02. J. Natl Cancer Inst.92, 388–396 (2000).
   PubMed Web of Science ®Google Scholar
• Tepper J, O’Connell M, Niedzwiecki D, et al. Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control – final report of intergroup 0114. J. Clin. Oncol.20, 1744–1750 (2002).
   PubMed Web of Science ®Google Scholar
• Tepper J, O’Connell M, Petroni G, et al. Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: initial results of intergroup 0114. J. Clin. Oncol.15, 2030–2039 (1997).
   PubMed Web of Science ®Google Scholar
• Mitry E, Fields A, Bleiberg H et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J. Clin. Oncol.26, 4906–4911 (2008).
   PubMed Web of Science ®Google Scholar
• O’Connell M, Martenson J, Wieand H, et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N. Engl. J. Med.331, 502–507 (1994).
   PubMed Web of Science ®Google Scholar
• Smalley S, Benedetti J, Williamson S, et al. Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144. J. Clin. Oncol.24, 3542–3547 (2006).
   PubMed Web of Science ®Google Scholar
• Kurt M, Ozkan L, Kurt E et al. Comparison of protracted infusion 5-fluorouracil and capecitabine in adjuvant chemoradiotherapy for rectal cancer. Hepatogastroenterology55(85), 1158–1163 (2008).
   PubMedGoogle Scholar
• Swedish Rectal Cancer Trial. Improved survival with preoperative radiotherapy in resectable rectal cancer. N. Engl. J. Med.336, 980–987 (1997).
   PubMed Web of Science ®Google Scholar
• Camma C, Giunta M, Fiorica F, et al. Preoperative radiotherapy for resectable rectal cancer: a meta-analysis. JAMA284, 1008–1015 (2000).
   PubMed Web of Science ®Google Scholar
• Colorectal Cancer Collaborative Group. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8507 patients from 22 randomised trials. Lancet358, 1291–1304 (2001).
   PubMed Web of Science ®Google Scholar
• Kapiteijn E, Marijnen C, Nagtegaal I et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N. Engl. J. Med.345, 638–646 (2001).
   PubMed Web of Science ®Google Scholar
• Dutch Colorectal Cancer Group. The TME trial after a median follow-up of 6 years. Ann. Surg.246(5), 693–701 (2007).
   PubMed Web of Science ®Google Scholar
• Peeters KC, Marijnen CA, Nagtegaal ID et al. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg246(5), 693–701 (2007).
   PubMed Web of Science ®Google Scholar
• Birgisson H, Pahlman L, Gunnarsson U et al. Adverse effects of preoperative radiation therapy for rectal cancer: long-term follow-up of the Swedish Rectal Cancer Trial. J. Clin. Oncol.23, 8697–8705 (2005).
   PubMed Web of Science ®Google Scholar
• Pollack J, Holm T, Cedermark B et al. Late Adverse Effects of Short Course Preoperative Radiotherapy in Rectal Cancer. Br. J. Surg.93, 1519–1525 (2006).
   PubMed Web of Science ®Google Scholar
• Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. N. Engl. J. Med.336(14), 980–987 (1997).
   PubMed Web of Science ®Google Scholar
• Kapiteijn E, Marijnen CA, Nagtegaal ID et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N. Engl. J. Med.345(9), 638–646 (2001).
   PubMed Web of Science ®Google Scholar
• Sauer R, Becker H, Hohenberger W et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N. Engl. J. Med.351(17), 1731–1740 (2004).
   PubMed Web of Science ®Google Scholar
• Sebag-Montefiore D, Stephens RJ, Steele R et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet373(9666), 811–820 (2009).
   PubMed Web of Science ®Google Scholar
• Bujko K, Nowacki MP, Nasierowska-Guttmejer A et al. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br. J. Surg.93(10), 1215–1223 (2006).
   PubMed Web of Science ®Google Scholar
• Siegel R, Burock S, Wernecke KD et al. Preoperative short-course radiotherapy versus combined radiochemotherapy in locally advanced rectal cancer: a multicentre prospectively randomised study of the Berlin Cancer Society. BMC Cancer9, 50 (2009).
   PubMed Web of Science ®Google Scholar
• Collette L, Bosset JF, den Dulk M et al. Patients with curative resection of cT3–4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. J. Clin. Oncol.25(28), 4379–4386 (2007).
   PubMed Web of Science ®Google Scholar
• Ngan SY, Fisher R, Burmeister BH et al. Promising results of a cooperative group Phase II trial of preoperative chemoradiation for locally advanced rectal cancer (TROG 9801). Dis. Colon Rectum48(7), 1389–1396 (2005).
   PubMed Web of Science ®Google Scholar
• Roh M, Colangelo L, Wieand S et al. Response to preoperative multimodality therapy predicts survival in patients with carcinoma of the rectum. Proc. Am. Soc. Clin. Oncol., 22 (2004) (Abstr 3505).
   Web of Science ®Google Scholar
• Hyams D, Mamounas E, Petrelli N et al. A clinical trial to evaluate the worth of preoperative multimodality therapy in patients with operable carcinoma of the rectum: a progress report of National Surgical Breast and Bowel Project Protocol R-03. Dis. Colon Rectum40, 131–139 (1997).
   PubMed Web of Science ®Google Scholar
• Sauer R, Becker H, Hohenberger W et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N. Engl. J. Med.351, 1731–1740 (2004).
   PubMed Web of Science ®Google Scholar
• Gérard JP, Conroy T, Bonnetain F et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3–4 rectal cancers: results of FFCD 9203. J. Clin. Oncol.24, 4620–4625 (2006).
   PubMed Web of Science ®Google Scholar
• Bosset J, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N. Engl. J. Med.355, 1114–1123 (2006).
   PubMed Web of Science ®Google Scholar
• Koeberle D, Burkhard R, von Moos R et al. Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer. Br. J. Cancer98(7), 1204–1209 (2008).
   PubMed Web of Science ®Google Scholar
• Wong J, Winter K, Meropol N et al. RTOG 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan versus capecitabine and oxaliplatin with concurrent radiation therapy for locally advanced rectal cancer. J. Clin. Oncol.26(Suppl. 15), 4021 (2008)
   Google Scholar
• Gunnlaugsson A et al. Multicentre Phase II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable colorectal cancer: The CORGI-L study. Eur. J. Cancer45(5), 807–813 (2008).
   PubMed Web of Science ®Google Scholar
• Willett C, Badizadegan K, Ancukiewicz M. Prognostic factors in stage T3N0 rectal cancer: do all patients require postoperative pelvic irradiation and chemotherapy? Dis. Colon Rectum42, 167–173 (1999).
   PubMed Web of Science ®Google Scholar
• Gunderson L, Sargent D, Tepper J et al. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol.22(10), 1785–1796 (2004).
   PubMed Web of Science ®Google Scholar
• Tepper JE, O’Connell MJ, Niedzwiecki D et al. Impact of number of nodes retrieved on outcome in patients with rectal cancer. J. Clin. Oncol.19(1), 157–163 (2001).
   PubMed Web of Science ®Google Scholar
• Gosens MJ, Klaassen RA, Tan-Go I et al. Circumferential margin involvement is the crucial prognostic factor after multimodality treatment in patients with locally advanced rectal carcinoma. Clin Cancer Res.13(22 Pt 1), 6617–6623 (2007).
   PubMed Web of Science ®Google Scholar
• Wang C, Zhou ZG, Yu YY et al. Occurrence and prognostic value of circumferential resection margin involvement for patients with rectal cancer. Int. J. Colorectal Dis.24(4), 385–390 (2009).
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Bevacizumab (Avastin™) for Treatment of Solid Tumors: Questions and Answers. National Cancer Institute Fact Sheet, MA, USA (2005)
   Google Scholar
• Willett CG, Boucher Y, di Tomaso E et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med.10(2), 145–147 (2004).
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med.350(23), 2335–2342 (2004).
   PubMed Web of Science ®Google Scholar
• Czito B, Bendell J, Willett C et al. Bevcizumab, oxaliplatin, and capecitabine with radiationtherapy in rectal cancer: Phase I trial results. Int. J. Rad. Oncol. Bio. Phy s.68(2), 472–478 (2007).
   PubMed Web of Science ®Google Scholar
• Willett C, Duda D, di Tomaso E et al. Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer. Nat. Clin. Pract. Oncol.4(5), 316–321 (2007).
   PubMedGoogle Scholar
• Willett CG, Duda DG, di Tomaso E et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary Phase II study. J. Clin. Oncol.27(18), 3020–3026 (2009)
   PubMed Web of Science ®Google Scholar
• US FDA. FDA Approves Erbitux For Colorectal Cancer. US FDA, MD, USA (2004).
   Google Scholar
• Saltz L, Rubin M, Hochster H et al. Cetuximab (IMC-C225) Plus irinotecan (cpt-11) is active in cpt-11-refractory colorectal cancer (crc) that expresses epidermal growth factor receptor (EGFR). In: ASCO Annual Meeting. Proc. Am. Soc. Clin. Oncol.20, 31 (2001) (Abstract 7).
   Google Scholar
• Machiels J, Sempoux C, Scalliet P et al. Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer. Ann. Oncol.18(4), 738–744 (2007).
   PubMed Web of Science ®Google Scholar
• Bengala C, Bettelli S, Bertolini F et al. Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer. Ann. Oncol20(3), 469–474 (2008).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Lang I, Dhaens G et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience. J. Clin. Oncol.26(Suppl.) (2008) (Abstract 2).
   Web of Science ®Google Scholar
• Bokemeyer C, Bondarenko I, Hartmann JT et al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience. J. Clin. Oncol.26(Suppl), 4000 (2008) (Abstract 4000).
   Web of Science ®Google Scholar
• Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol.26(10), 1626–1634 (2008).
   PubMed Web of Science ®Google Scholar
• Khambata-Ford S, Garrett CR, Meropol NJ et al. xpression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J. Clin. Oncol.25(22), 3230–3237 (2007).
   PubMed Web of Science ®Google Scholar
• Lievre A, Bachet JB, Boige V et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J. Clin. Oncol.26(3), 374–379 (2008).
   PubMed Web of Science ®Google Scholar
• Cengel KA, Voong KR, Chandrasekaran S et al. Oncogenic K-Ras signals through epidermal growth factor receptor and wild-type H-Ras to promote radiation survival in pancreatic and colorectal carcinoma cells. Neoplasia9(4), 341–348 (2007).
   PubMed Web of Science ®Google Scholar
• McKenna WG, Muschel RJ, Gupta AK, Hahn SM, Bernhard EJ. The RAS signal transduction pathway and its role in radiation sensitivity. Oncogene22(37), 5866–5875 (2003).
   PubMed Web of Science ®Google Scholar
• Czito BG, Bendell JC, Willett CG et al. Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results. Int. J. Radiat. Oncol. Biol. Phys.68(2), 472–478 (2007).
   PubMed Web of Science ®Google Scholar
• Willett CG, Duda DG, di Tomaso E et al. Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer. Nat Clin Pract Oncol.4(5), 316–321 (2007).
   PubMedGoogle Scholar
• Avallone A, Delrio P, Pecori B et al. Phase II study of two different schedules of bevacizumab (BEV) with oxaliplatin (OXA), raltitrexed, levo-folinic acid (LFA) and fluorouracil (5FU) during pelvic RT in high-risk locally advanced rectal cancer (LARC) patients (pts). Presented at: Gastrointestinal Cancers Symposium, CA, USA (2009) (Abstract 466).
   Google Scholar
• Marijnen CA, Rutten H, de Wilt H et al. Preoperative chemoradiotherapy regimen with capecitabine and bevacizumab in locally advanced rectal cancer: A feasibility study of the Dutch Colorectal Cancer Group (DCCG). J. Clin. Oncol.26(Suppl. 15), 15040 (2008) (Abstract 15040).
   Google Scholar
• DiPetrillo TA, Pricolo V, Sikov WM et al. Neoadjuvant bevacizumab, oxaliplatin, 5-fluorouracil, and radiation in clinical stage II-III rectal cancer. J. Clin. Oncol.26(Suppl. 15S), 15041 (2008) (Abstract 15041).
   Google Scholar
• Crane CH, Eng C, Feig BW et al. Phase II trial of neoadjuvant bevacizumab (BEV), capecitabine (CAP), and radiotherapy (XRT) for locally advanced rectal cancer. J. Clin. Oncol.26(Suppl. 15S), 4091 (2008) (Abstract 4091).
   Google Scholar
• Machiels JP, Sempoux C, Scalliet P et al. Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer. Ann. Oncol.18(4), 738–744 (2007).
   PubMed Web of Science ®Google Scholar
• Horisberger K, Treschl A, Mai S et al. Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT Trial. Int. J. Radiat. Oncol. Biol. Phys.. (2009).
   PubMedGoogle Scholar
• Rodel C, Arnold D, Hipp M et al. Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer. Int. J. Radiat. Oncol. Biol. Phys.70(4), 1081–1086 (2008).
   PubMed Web of Science ®Google Scholar
• Pinto C, Di Fabio F, Di Bisceglie M et al. Panitumumab, 5-fluorouracil, and oxaliplatin with concurrent radiotherapy in locally advanced rectal cancer: Preliminary safety results of the StarPan-STAR-02 Study. Presented at: Gastrointestinal Cancers Symposium. CA, USA, 15–17 January 2009 (Abstract 472).
   Google Scholar